HC Wainwright & Co. reiterated coverage on Ocugen with a new price target
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
HC Wainwright & Co. reiterated coverage of Ocugen with a rating of Buy and set a new price target of $10.00 from $12.00 previously